Skip to main content

Samsara BioCapital — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

132
Companies
$14.2B
Total invested
$107.7M
Avg. check
16
Industries
Biotechnology 22Health Care 14Medical 13Therapeutics 11Life Science 7Pharmaceutical 6+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 25–48 of 132
Psivant Therapeutics
December 2025

Psivant Therapeutics is a biotechnology company that offers drug design, biology research, and development services.

Biopharma · Watertown$47.5M Series A
Centessa Pharmaceuticals
November 2025

Centessa Pharmaceuticals is a pharmaceutical company that focuses on drug development to address significant medical needs.

Biotechnology · Cambridge$250.0M Post-IPO Equity
Rani Therapeutics
October 2025

Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes.

Biotechnology · San Jose$60.3M Post-IPO Equity
Excellergy
October 2025

Excellergy develops immunology-based therapies focused on treating allergic diseases through novel biologic drug candidates.

Biotechnology · Palo Alto$70.0M Series A
Cypherpunk Technologies (formerly Leap Therapeutics)
October 2025

Cypherpunk is a biopharmaceutical company developing antibody therapies for cancer while executing a digital-asset treasury strategy.

Biotechnology · Cambridge$58.9M Post-IPO Equity
IO Biotech
September 2025

IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.

Biotechnology · Copenhagen$6.6M Post-IPO Equity
Pepgen
September 2025

PepGen is empowering nucleic acid therapeutics to go the distance.

Biotechnology · Oxford$115.0M Post-IPO Equity
Dewpoint Therapeutics
September 2025

Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates.

Biotechnology · Boston$59.1M Series D
Enlaza Therapeutics
September 2025

Enlaza Therapeutics is a biotechnology research company.

Biopharma · La Jolla$15.0M Venture - Series Unknown
Prime Medicine
August 2025

Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.

Biotechnology · Cambridge$5.0M Post-IPO Equity
Shenandoah Therapeutics
June 2025

Shenandoah Therapeutics is a biotechnology company.

Health Care · South San Francisco$20.0M Seed
Spyglass Pharma
June 2025

Spyglass Pharma provides medicine for ophthalmic diseases.

Delivery · Aliso Viejo$75.0M Series D
Alpheus Medical
May 2025

Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers.

Biotechnology · Oakdale$52.0M Series B
A2 Biotherapeutics
May 2025

A2 Biotherapeutics develops T cell therapies targeting solid tumors precisely.

Biotechnology · Agoura Hills$300K Grant
Surrozen
March 2025

Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.

Biotechnology · South San Francisco$175.0M Post-IPO Equity
Abcuro
February 2025

Abcuro develops immunotherapies to treat autoimmunity and cancer.

Biotechnology · Newton$200.0M Series C
Normunity
January 2025

Normunity develops precision immuno-oncology medicines that enable normal immunity against cancer.

Biotechnology · New Haven$75.0M Series B
Ottimo Pharma
December 2024

Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.

Biotechnology · Sandwich$140.0M Series A
Janux Therapeutics
December 2024

Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.

Biotechnology · La Jolla$350.0M Post-IPO Equity
Enara Bio
October 2024

Ervaxx is illuminating the immune interface to develop new cancer therapies.

Biopharma · Oxford$32.5M Series B
ImmunOs Therapeutics
September 2024

ImmunOs Therapeutics is a clinical-stage biotechnology company.

Biotechnology · Schlieren$11.0M Series C
Seismic Therapeutic
September 2024

Seismic Therapeutic is a biotechnology company developing machine-learning technology for immunology drug development.

Biotechnology · Watertown$25.0M Series B
OrsoBio
September 2024

OrsoBio is a clinical-stage biopharmaceutical company that develops therapies to treat severe metabolic disorders.

Biopharma · Palo Alto$67.0M Series B
EGenesis
September 2024

EGenesis is a gene editing and genome engineering company developing human-compatible engineered organs to treat diseases.

Biopharma · Cambridge$191.0M Series D

Where Samsara BioCapital invests

Biotechnology22
Health Care14
Medical13
Therapeutics11
Life Science7
Pharmaceutical6

About Samsara BioCapital's portfolio

How many companies has Samsara BioCapital invested in?▸

Samsara BioCapital has invested in 132 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Samsara BioCapital invest in?▸

Samsara BioCapital's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 16 different industry categories.

What is Samsara BioCapital's largest investment?▸

Among tracked funding rounds, Janux Therapeutics received $350.0M in a Post-IPO Equity round. Samsara BioCapital's total known invested capital is $14.2B.

What is the average investment size for Samsara BioCapital?▸

Samsara BioCapital's average investment size is $107.7M across its portfolio of 132 companies.

What are Samsara BioCapital's most recent investments?▸

Recent Samsara BioCapital portfolio additions include Psivant Therapeutics, Centessa Pharmaceuticals, Rani Therapeutics, Excellergy, Cypherpunk Technologies (formerly Leap Therapeutics). These companies were founded in 2020 or later.

Reach the founders behind these 132 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →